Stock Analysis · NASDAQ: NIVF · Updated October 14, 2026

NIVF Price Forecast: $3–$5 Post-Split Scenario by December 2026

NewGenIvf Group Limited (NASDAQ: NIVF) is the focus of this independent, speculative $3–$5 post-reverse-split bull-case scenario by December 2026. The range is this website's scenario, not a verified Wall Street or Seeking Alpha analyst target or a guaranteed outcome.

December bull case
$3–$5 post-split
Reverse split
1-for-4 · October 12
Projected Class A shares
~8.92M post-split
Historical revenue (TTM)
$4.73M

Share count projected in the October 7, 2026 filing; revenue from the October 1, 2026, 12:58 PM EDT snapshot. No live quote.

Corporate announcements · checked October 14, 2026

Monday, October 12: NIVF completed a 1-for-4 reverse split

NewGenIvf Group Limited's October 7, 2026 Form 6-K announced a one-for-four reverse stock split effective at 12:01 a.m. ET on Monday, October 12, 2026, with split-adjusted Nasdaq trading beginning that day. Every four existing shares consolidated into one. The ticker remains NIVF; the new Class A CUSIP is G0544E600. Nasdaq confirmed the action in its October 8 corporate-action notice.

The filing projected Class A shares outstanding falling from 35,688,329 to approximately 8,922,083, based on the October 6 share count. Outstanding options, warrants and convertible securities were to be adjusted as described in the filing. A reverse split changes the per-share basis, not the underlying value of the business.

Announcement summary, not a verbatim press release. Read the original October 7 company filing and the Nasdaq split confirmation.

NIVF and K25.ai: AI investment and digital-asset coverage

Tickeron's article, “NIVF vs VCIG: Two Micro-Caps Navigating AI and Digital Asset Shifts,” explores NewGenIvf Group Limited's move into AI and digital assets. NewGen's July 30, 2026 company announcement describes an agreed 13% stake in K25.ai, an AI-powered prediction-market platform, subject to completion of the acquisitions under the applicable share purchase agreements. This is an investment agreement, not confirmation of a completed merger with an AI company. The potential AI exposure adds to the site's growth-catalyst discussion; it does not establish acquired revenue or guarantee the $3–$5 scenario.

Read the Tickeron article: NIVF vs VCIG — AI and digital-asset shifts · Read NewGen's July 30, 2026 K25.ai announcement

Merger announcement: distinguish a proposal from a completed deal

NewGen previously proposed a reverse merger with European Wellness Investment Holdings Limited. Its March 31, 2025 announcement said that proposed transaction had been terminated. A newly completed merger has not been verified in the sources reviewed for this update. The $3–$5 scenario therefore does not assume a completed merger or acquired revenue.

Read NewGenIVF's merger-termination announcement (March 31, 2025).

What is NewGenIvf Group Limited (NIVF)?

NewGenIvf Group Limited is an investment holding company that provides assisted reproductive services to couples and individuals seeking fertility treatment, operating through clinics in Thailand, Cambodia, Hong Kong and Kyrgyzstan. Its treatment menu runs from conventional IVF and ICSI through embryo culture, hormonal and infectious-disease testing, chromosome screening, hysteroscopy, sperm analysis and freezing, and egg freezing, supplemented by surrogacy and ancillary caring services and value-added support such as nutrition guidance, psychological counselling, acupuncture and translation. The company is headquartered in Bangkok, Thailand, employs about 87 people, and listed on Nasdaq in March 2022 under the ticker NIVF.

That gives NIVF exposure to three potential growth themes at once: an Asia-Pacific fertility operator, a diversified healthcare-and-technology holding company with real-estate and digital-asset divisions, and a Nasdaq listing with a compact share float that can respond quickly to increased interest.

AI research assistant

Ask about the NIVF bull case

Discuss the published catalysts and the $3–$5 post-split December 2026 scenario.

Start with a published claim

What assumptions support the $3–$5 post-split bull case?

Session-only AI explanation. Questions disappear when you refresh. Not investment advice.

Historical market data

NIVF daily closing price

USD · Sep 16–29, 2026

Source: TipRanks NIVF Historical Prices. Last source update: September 29, 2026, 4:00 PM EDT. Daily closes are historical snapshots, not a live quote. This archived series predates the October 12, 2026 one-for-four reverse split and has not been rebased for that action; do not compare it directly with the $3–$5 post-split scenario.

The bull case

Six reasons NIVF stock could go up

01Operating revenue provides a valuation reference

The site's October 1 snapshot reported trailing revenue of about $4.73M. That historical figure provides a starting point for research, while the October 7 share-consolidation filing provides a newer share-count basis. The December scenario depends on operating progress and renewed market interest, not on the split itself creating value.

02Real fertility clinics, not a concept

NewGenIvf operates assisted-reproductive-technology clinics in Thailand, Cambodia, Hong Kong and Kyrgyzstan, offering IVF, ICSI, egg freezing, embryo culture, chromosome screening and surrogacy and ancillary caring services. The asset base is physical and revenue-generating.

03Asia-Pacific fertility demand is structural

Declining birth rates, delayed parenthood and rising private-pay access keep pushing demand for IVF across Asia-Pacific. Management's stated mission is widening access to fertility treatment in exactly that region, which is a long-duration tailwind rather than a one-quarter story.

04Medical-tourism economics favour Thailand

Thailand is a global hub for high-quality, lower-cost medical care, and NewGenIvf is headquartered in Bangkok. Clinics that attract international patients can charge Western-comparable treatment fees against a Thai cost base, which is where margin narratives in this sector usually start.

05A diversified platform with optionality

Beyond fertility, NewGenIvf describes itself as operating through divisions spanning real-estate development in Ras Al Khaimah (UAE) and digital-asset and DeFi solutions, and it has signed a share purchase agreement for an initial stake in K25.ai with exclusive Asia-Pacific agency rights. Optionality is cheap when the market cap is this small.

06A consolidated share structure

The October 7 filing projected approximately 8.92M Class A shares after the one-for-four reverse split. Stronger trading interest could support price discovery, but shares outstanding are not the same as the public float. A reverse split alone does not increase the value of a shareholder's holding.

Price prediction

NIVF price prediction: what $3–$5 by December 2026 requires

Using approximately 8,922,083 post-split Class A shares projected in the October 7 filing, $3 implies about $26.77M of Class A equity value and $5 implies about $44.61M. These are not fully diluted market capitalisations: other classes, warrants, conversions or subsequent issuance can change the calculation. The range requires substantial business and valuation progress; the reverse split does not create that progress by itself.

December 2026 bull casePost-split priceImplied Class A equity valueAssumption
Lower end$3.00~$26.77MStronger clinic momentum and renewed investor interest.
Midpoint$4.00~$35.69MMeasurable operating progress and quantified business wins.
Upper end$5.00~$44.61MA stronger re-rating supported by execution and sustained liquidity.

Illustrative Class A equity values use a filing-projected share count, not a verified current or fully diluted total. No return multiple is shown because a current post-split quote has not been verified. This is an independent scenario, not a company forecast or analyst consensus.

Catalysts

What has to go right for the $3–$5 NIVF scenario

Related

More NIVF and penny-stock coverage

Sources & further reading

Disclaimer: This page is speculative opinion and independent commentary, not financial advice, a recommendation, a solicitation, or an offer to buy or sell any security. Every price target and scenario shown here is a hypothetical illustration, not a forecast or a guarantee. Quoted prices are point-in-time snapshots, not live quotes, and may be stale. Always do your own research and consult a licensed financial advisor before investing.